• May 20, 2024

All About BioTech Leader Leen Kawas

Leen Kawas is the Co-Founder and Managing Partner at Propel Bio Partners. She has been one of the driving forces behind Propel’s rapid rise over the past few years. In an era where biotech startups are being valued and funded like never before, it is in the best interest of businesses to partner with skilled entrepreneurs who can help them succeed. She is known in the biotech industry for her extensive experience in the industry.

Her Educationshe graduated from Jordan University with a degree in pharmacy before proceeding to Washington State University for A Ph.D. in molecular pharmacology & toxicology.

Analyzing the Market

Leen Kawas believes the biotech ecosystem has changed drastically in recent years. With new biotech startups coming out daily, getting a product to market is extremely important for young entrepreneurs. She has said she will work with Propel’s founders and CEOs to analyze their portfolios and find an exit plan to maximize their investment. Kawas believes there are patent issues, capital availability, and regulatory barriers they need to overcome to succeed.

Career

She is the former CEO at Athira Life Sciences and was the lead author of the publication “A Pharmacogenomic Approach to Drug Discovery,” published in Pharmacogenomics & Therapeutics. She has been an investor in Propel Bio Partners since 2014. Before working at Athira Life Sciences, Leen was a managing director for Tresserra Capital Management and a managing director for Bioconcept Advisors Corporation.

Achievement

Leen Kawas has won several awards for her work with various biotech companies. She has been named by BioWorld as one of the “World’s Most Influential Women in Biotech” multiple times. She was also awarded biotech’s highest honor, the John Dirks Award, from Biotechnology Innovation Organization (BIO) in 2015 and 2013.

Leen Kawas is one of the most knowledgeable individuals in the biotech industry. She is committed to ensuring Propel Bio Partners succeed and find the best exits for their portfolio. Her hard work and long-term vision for the company will help Propel reach its goals of being one of the top biotech investment firms for years to come.